LP-51
General Information
DRACP ID DRACP00833
Peptide Name LP-51
Sequence LEANIEELLKKAEEQQKKNEEELKKLEX
Sequence Length 28
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
Active ACP
Activity Information
Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|---|
TZM-bl | Human papillomavirus-related endocervical adenocarcinoma | Carcinoma | 50% Cytotoxicity=434.03±90.38µM | CellTiter 96 AQueous One Solution assay | 48h | 1 |
MT-4 | Human acute lymphoblastic leukemia cell line | Leukemia | 50% Cytotoxicity=135.07±32.3µM | CellTiter 96 AQueous One Solution assay | 48h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity HEK293T cells: 50% Cytotoxicity=130.07±15.27 µM; PBMC: 50% Cytotoxicity=46.83±4.65 µM
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer; Antiviral
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Acetylation
C-terminal Modification Amidation
Other Modification X(28)= Lysine with palmitoylated side group
Chiral L
Physicochemical Information
Formula C141H239N37O49
Absent amino acids CDFGHMPRSTVWY
Common amino acids E
Mass 382845
Pl 4.43
Basic residues 6
Acidic residues 9
Hydrophobic residues 8
Net charge -3
Boman Index -8581
Hydrophobicity -149.29
Aliphatic Index 90.71
Half Life
/
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 2
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 30089693
Title Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus
Year 2018
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available